Introduction
Cervari
is a vaccine for cervical cancer in Indonesia, which is intended for both young
girls and adult women (aged 10 years s / d 55 years) for the prevention of
cervical cancer.
The
vaccine contains antigens for HPV types 16 and 18 cause more than 70% of
cervical cancer cases in the world.
GSK's
cervical cancer vaccine provides 100% protection against human papillomavirus
(HPV) types 16 and 18 are associated with lesions of pre-kanker.
Cervarix
also provide additional protection against other oncogenic HPV types are HPV
types 45, 31 and 52.
Cervarix
is formulated with an adjuvant system technology ASO4. ASO4 encourage the
formation of a stronger immune response and durable than the aluminum adjuvant
tradisional.
All
women are at risk of cervical cancer during their lifetime, regardless of age
and lifestyle
HPV
is a common virus, easily passed through genital skin contact. Both
teenage girls and adult women at risk for cervical cancer is caused by repeated
infection of HPV cause kanker.
Estimated
that up to 50-80% of women will have an HPV infection in their lifetime, 7-9
and up to 50% percent of these infections could potentially cause cancer. 9-11
The risk of infection since the first sexual contact.
Most
HPV infections go away on its own, but some will stay. 13 Unlike other viruses,
when a woman has been infected with HPV, does not mean she will have immunity
to this virus. 7.14-19 Therefore, even if a woman has been exposed to HPV, she
still has the risk of recurrent infection of HPV types are the same or
different, and remain at risk for cervical cancer.
Indications
Cervarix
In
Indonesia, GSK's cervical cancer vaccine aimed at teenage girls and adult women
to prevent cervical cancer by protecting from infection and the incidence of
persistent infection at the stage of CIN 2 and more severe lesions caused by
human papillomavirus (HPV) types 16 and 18. This vaccine has demonstrated
efficacy against persistent infection caused by oncogenic HPV types other than
HPV 16 and HPV 18.
Vaccination
schedule for GSK's cervical cancer vaccine consists of three doses, given at
months 0, the 1st and the 6th.
Cervarix
has been tested on 40,000 study subjects and has demonstrated a good level of
tolerance.
In
the world, every two minutes a woman dies of cervical cancer.
In
Indonesia, cervical cancer is the number one cancer that most commonly affects
women in Indonesia.
Cervical
cancer is a cancer that can affect women with diverse backgrounds and different
ages all over the world. Starting with the cervix - the part of the uterus (or
womb) and then reach the vagina - and gradually will spread if not given
treatment.
Cervical
cancer can often infect and kill women in the productive age (30-50 years of
age), often at the time they still have social and economic responsibilities
towards children and other family members.
Pap
smears can detect early-stage cervical cancer by identifying the cell changes
on the cervix.
In
general, will not be visible symptoms in the early stages of cancer serviks.
The
risk of developing cervical cancer in women who are not screened regularly is
five times higher than the teratur.
Screening
is important because it can help detect cervical cancer development, but it can
not prevent HPV infection.
There
are 15 types of cancer-causing HPV types can lead to cervical cancer; HPV 16
and 18, causing more than 70% of cervical cancer in the Asia Pacific region and
the world.
HPV
is a common virus.
HPV
easily transmitted through genital skin contact
Both
teenage girls and adult women at risk for cervical cancer is caused by
infection or recurrent infection caused by HPV causes cancer.
Most
HPV infections go away on its own, but some will stay. 26 Unlike other viruses,
when a woman infected with HPV virus, does not mean she will have immunity to
this virus. 3.27-32 Therefore, although a woman has been exposed to HPV, she is
still at risk for recurrent infection of HPV types are the same or different,
and remain at risk of developing cancer serviks.
The
vaccine targets HPV types 16 and 18 have the potential to prevent more than 70%
of cervical cancer incidence 19
In
the future, vaccination with screening can reduce the risk of cervical cancer
compared with screening alone and can reduce the number of abnormal screening
that require follow-up significantly.
HPV
and Cervical Cancer
In
the world, about 500,000 women are diagnosed with cervical cancer and an
average of 270,000 deaths annually. Women who are sexually active are infected risk of cervical cancer or early
stage disease regardless of age or lifestyle.
- New cases of cervical cancer 40-45 / 9-10 days
-
The number of deaths due to cervical cancer is 20-25 / hari9-10
-
Every one hour, one woman died of cancer serviks9-10
How
to detect cervical cancer?
HPV
- the virus that causes cervical cancer
-
HPV types 16, 18, 45, 52 and 31 are responsible for more than 80% of cervical
cancer cases in Asia Pasifik
Every
woman at risk of contracting cervical cancer during their lifetime, regardless
of age and lifestyle. An estimated 50-80% of women were infected with HPV
through sexual contact in their lives, 3,21,22 and potentially cause cancer by
50%. 22-24 The risk of infection since the first sexual contact.
Prevention
by HPV vaccination
The
vaccine will enhance the ability of the immune system to recognize and destroy
the virus when it enters the body, before the infection.
No comments:
Post a Comment